JP2015527387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527387A5 JP2015527387A5 JP2015530495A JP2015530495A JP2015527387A5 JP 2015527387 A5 JP2015527387 A5 JP 2015527387A5 JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015527387 A5 JP2015527387 A5 JP 2015527387A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- heteroaryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 255
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 79
- 125000000623 heterocyclic group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 239000001257 hydrogen Substances 0.000 claims description 49
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 34
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- -1 trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 125000001589 carboacyl group Chemical group 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216017.2 | 2012-09-07 | ||
| GBGB1216017.2A GB201216017D0 (en) | 2012-09-07 | 2012-09-07 | Inhibitor compounds |
| PCT/GB2013/052360 WO2014037750A1 (en) | 2012-09-07 | 2013-09-09 | Inhibitor compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Division JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527387A JP2015527387A (ja) | 2015-09-17 |
| JP2015527387A5 true JP2015527387A5 (https=) | 2017-09-07 |
| JP6216791B2 JP6216791B2 (ja) | 2017-10-18 |
Family
ID=47137117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530495A Active JP6216791B2 (ja) | 2012-09-07 | 2013-09-09 | 阻害剤化合物 |
| JP2017182377A Expired - Fee Related JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Expired - Fee Related JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9409907B2 (https=) |
| EP (2) | EP3293183B1 (https=) |
| JP (2) | JP6216791B2 (https=) |
| CN (1) | CN104837829B (https=) |
| AU (2) | AU2013311434B2 (https=) |
| BR (1) | BR112015004489B1 (https=) |
| CA (1) | CA2884006C (https=) |
| CY (1) | CY1119714T1 (https=) |
| DK (2) | DK2892889T3 (https=) |
| ES (2) | ES2655194T3 (https=) |
| GB (1) | GB201216017D0 (https=) |
| HR (1) | HRP20171835T1 (https=) |
| HU (1) | HUE036259T2 (https=) |
| LT (1) | LT2892889T (https=) |
| NO (1) | NO2892889T3 (https=) |
| PL (1) | PL2892889T3 (https=) |
| PT (1) | PT2892889T (https=) |
| RS (1) | RS56750B1 (https=) |
| RU (1) | RU2673079C2 (https=) |
| SI (1) | SI2892889T1 (https=) |
| SM (1) | SMT201700596T1 (https=) |
| WO (1) | WO2014037750A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| CA2978149C (en) | 2008-03-21 | 2019-02-12 | The General Hospital Corporation | Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| AU2014308616B2 (en) * | 2013-08-23 | 2018-12-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| CN107613769A (zh) * | 2015-02-17 | 2018-01-19 | 润新生物公司 | 某些化学实体、组合物和方法 |
| FI3283642T3 (fi) | 2015-04-17 | 2024-01-11 | Crossfire Oncology Holding B V | Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan |
| DK3305785T3 (da) | 2015-05-29 | 2021-10-11 | Teijin Pharma Ltd | Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf |
| KR102591886B1 (ko) * | 2015-07-21 | 2023-10-20 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| CN109843858B (zh) | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| LT3546458T (lt) * | 2016-11-28 | 2021-05-10 | Teijin Pharma Limited | ((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio |
| SI3546456T1 (sl) | 2016-11-28 | 2022-04-29 | Teijin Pharma Limited | Kristal derivata pirido(3,4-D)pirimidina ali njegovega solvata |
| GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| JP2020524169A (ja) * | 2017-06-20 | 2020-08-13 | ジ・インスティチュート・オブ・キャンサー・リサーチ：ロイヤル・キャンサー・ホスピタル | 方法および医学的利用 |
| EP3701304B1 (en) | 2017-10-26 | 2022-05-04 | CommScope Connectivity Belgium BVBA | Telecommunications system |
| GB201809458D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| PT4053118T (pt) | 2019-10-30 | 2024-12-05 | Genfleet Therapeutics Shanghai Inc | Composto cíclico fundido heterocíclico substituído, método de preparação deste e utilização farmacêutica deste |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| EP4090663A1 (en) * | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| US11267788B2 (en) * | 2020-07-16 | 2022-03-08 | Dermavant Sciences GmbH | Isoquinoline compounds and their use in treating AhR imbalance |
| WO2022037592A1 (zh) * | 2020-08-17 | 2022-02-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物 |
| MX2023005747A (es) | 2020-11-18 | 2023-07-28 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. |
| CN115583946B (zh) * | 2021-07-06 | 2026-01-16 | 赛诺哈勃药业（成都）有限公司 | 杂环化合物及其作为cdk抑制剂的用途 |
| CN116354957A (zh) * | 2021-12-16 | 2023-06-30 | 药捷安康(南京)科技股份有限公司 | Cdk9抑制剂及其用途 |
| WO2024238574A1 (en) * | 2023-05-15 | 2024-11-21 | Aleksia Therapeutics, Inc. | Cdk inhibitor compounds |
| WO2025038785A1 (en) * | 2023-08-16 | 2025-02-20 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications |
| CN117800875B (zh) * | 2023-12-21 | 2024-10-22 | 泰州精英化成医药科技有限公司 | 一种反式-(N-Boc-4-氨基环己基)乙酸的制备方法 |
| TW202545531A (zh) * | 2024-01-17 | 2025-12-01 | 美商依安彼克醫療有限公司 | 氮—喹唑啉化合物之使用方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
| US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| HUT76853A (en) | 1994-11-14 | 1997-12-29 | Warner Lambert Co | 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| CZ20022475A3 (cs) | 2000-01-25 | 2003-03-12 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidin-2,7-diaminové inhibitory kinázy |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003000011A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| JP2005516927A (ja) | 2001-12-13 | 2005-06-09 | アボット・ラボラトリーズ | 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物 |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1485390B1 (en) | 2002-03-07 | 2008-10-08 | F. Hoffman-la Roche AG | Bicyclic pyridine and pyrimidine p38 kinase inhibitors |
| CA2492112A1 (en) * | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| JP4820094B2 (ja) | 2002-11-12 | 2011-11-24 | アボット・ラボラトリーズ | ヒスタミン−３受容体リガンドとしての２環式置換アミン |
| US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| NZ565040A (en) | 2005-06-28 | 2010-05-28 | Sanofi Aventis | Isoquinoline derivatives as inhibitors of RHO-kinase |
| EP1979348B1 (en) * | 2005-12-21 | 2012-01-18 | Abbott Laboratories | Anti-viral compounds |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| WO2009084695A1 (ja) * | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
| GB201011182D0 (en) | 2010-07-02 | 2010-08-18 | Wireless Fibre Systems Ltd | Riser wireless communications system |
| EP2598508B1 (en) | 2010-07-30 | 2015-04-22 | Nerviano Medical Sciences S.r.l. | Isoxazolo-quinazolines as modulators of protein kinase activity |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| TW201307292A (zh) | 2010-12-17 | 2013-02-16 | Hoffmann La Roche | 經取代之６，６－稠合含氮雜環化合物及其用途 |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US8883793B2 (en) | 2010-12-29 | 2014-11-11 | Development Center For Biotechnology | Tubulin inhibitors and methods of using the same |
| ES2602791T3 (es) * | 2011-01-26 | 2017-02-22 | Nerviano Medical Sciences S.R.L. | Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
| KR101923250B1 (ko) | 2011-07-29 | 2018-11-28 | 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 | 유방암의 치료 |
| EP2766352B1 (en) | 2011-10-12 | 2018-06-06 | University Health Network (UHN) | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP2961409A1 (en) | 2013-02-26 | 2016-01-06 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| WO2015082990A1 (en) | 2013-12-06 | 2015-06-11 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP3119908A4 (en) | 2014-03-11 | 2018-02-21 | The Council Of The Queensland Institute Of Medical Research | Determining cancer aggressiveness, prognosis and responsiveness to treatment |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| US10611765B2 (en) | 2014-11-06 | 2020-04-07 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors |
| GB201522532D0 (en) | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| JP2020524169A (ja) | 2017-06-20 | 2020-08-13 | ジ・インスティチュート・オブ・キャンサー・リサーチ：ロイヤル・キャンサー・ホスピタル | 方法および医学的利用 |
-
2012
- 2012-09-07 GB GBGB1216017.2A patent/GB201216017D0/en not_active Ceased
-
2013
- 2013-09-09 WO PCT/GB2013/052360 patent/WO2014037750A1/en not_active Ceased
- 2013-09-09 EP EP17192253.7A patent/EP3293183B1/en active Active
- 2013-09-09 CA CA2884006A patent/CA2884006C/en active Active
- 2013-09-09 CN CN201380057967.7A patent/CN104837829B/zh not_active Expired - Fee Related
- 2013-09-09 NO NO13760106A patent/NO2892889T3/no unknown
- 2013-09-09 RU RU2015112580A patent/RU2673079C2/ru active
- 2013-09-09 SI SI201330829T patent/SI2892889T1/sl unknown
- 2013-09-09 DK DK13760106.8T patent/DK2892889T3/en active
- 2013-09-09 SM SM20170596T patent/SMT201700596T1/it unknown
- 2013-09-09 EP EP13760106.8A patent/EP2892889B1/en active Active
- 2013-09-09 AU AU2013311434A patent/AU2013311434B2/en not_active Ceased
- 2013-09-09 JP JP2015530495A patent/JP6216791B2/ja active Active
- 2013-09-09 PL PL13760106T patent/PL2892889T3/pl unknown
- 2013-09-09 ES ES13760106.8T patent/ES2655194T3/es active Active
- 2013-09-09 ES ES17192253T patent/ES2742442T3/es active Active
- 2013-09-09 BR BR112015004489-1A patent/BR112015004489B1/pt not_active IP Right Cessation
- 2013-09-09 US US14/426,549 patent/US9409907B2/en active Active
- 2013-09-09 RS RS20171314A patent/RS56750B1/sr unknown
- 2013-09-09 HU HUE13760106A patent/HUE036259T2/hu unknown
- 2013-09-09 PT PT137601068T patent/PT2892889T/pt unknown
- 2013-09-09 HR HRP20171835TT patent/HRP20171835T1/hr unknown
- 2013-09-09 DK DK17192253.7T patent/DK3293183T3/da active
- 2013-09-09 LT LTEP13760106.8T patent/LT2892889T/lt unknown
-
2016
- 2016-04-06 US US15/091,887 patent/US9890157B2/en not_active Expired - Fee Related
- 2016-04-06 US US15/091,980 patent/US9834552B2/en active Active
-
2017
- 2017-09-22 JP JP2017182377A patent/JP6496376B2/ja not_active Expired - Fee Related
- 2017-11-27 AU AU2017268488A patent/AU2017268488B2/en not_active Ceased
- 2017-12-29 CY CY20171101358T patent/CY1119714T1/el unknown
-
2018
- 2018-01-08 US US15/864,499 patent/US10479788B2/en active Active
-
2019
- 2019-10-10 US US16/598,717 patent/US11046688B2/en not_active Expired - Fee Related
-
2021
- 2021-05-13 US US17/319,231 patent/US11897877B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527387A5 (https=) | ||
| JP2015529217A5 (https=) | ||
| SI2922844T1 (en) | N-PYROLIDINYL, N'-PYRAZOLYL-WATER, TIOUREE, GVANIDINE AND CYANOGVANIDINE COMPOUNDS AS THE BLOOD KINASE INHIBITORS | |
| CN114222743A (zh) | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 | |
| JP2014504622A5 (https=) | ||
| JP2016537382A5 (https=) | ||
| JP2015537001A5 (https=) | ||
| JP2017524025A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2019514874A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| JP2015143283A5 (https=) | ||
| JP2014500296A5 (https=) | ||
| JP2017509586A5 (https=) | ||
| JP2009536620A5 (https=) | ||
| JP2016506961A5 (https=) | ||
| JP2016516043A5 (https=) | ||
| JP2017508782A5 (https=) | ||
| JP2017523169A5 (https=) | ||
| JP2018516904A5 (https=) | ||
| JP2015535851A5 (https=) | ||
| JP2016513696A5 (https=) | ||
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2015508092A5 (https=) | ||
| JP2017521375A5 (https=) |